A Kidney Disease With No Good Options Just Got Its Sixth FDA-Approved Drug
The FDA just approved Vera Therapeutics' Trutakna for IgA nephropathy, a kidney disease that barely had any treatments three years ago. Now it has six approved drugs, Wall Street is projecting blockbuster sales, and the real competition is just getting started.
Your kidneys filter about 45 gallons of blood every single day. Now imagine a disease where your own immune system slowly clogs those filters with garbage. That's IgA nephropathy in a nutshell, and for decades, patients had almost nothing to fight it with.
On July 7, the FDA approved Trutakna (atacicept-vymj) from Vera Therapeutics, making it the latest weapon in what has become a remarkably crowded battlefield. Two years ago, there was basically one IgAN-specific drug on the market. Now there are six.
But Trutakna isn't just another me-too approval. It works differently from everything else out there, and Wall Street thinks it could be worth $2.5 billion in annual sales by 2033. So what makes this one special?
The Disease That Hides in Plain Sight
IgA nephropathy (IgAN) is the most common type of kidney inflammation found on biopsy worldwide. It affects roughly 200,000 people in the U.S. alone, with even higher rates in Asia, where it accounts for up to 40% of kidney biopsies.
The problem starts with a protein called IgA1. In healthy people, IgA1 helps patrol the mucosal surfaces of your gut and airways, fending off infections. In IgAN patients, their B cells (a type of immune cell) produce a defective version called galactose-deficient IgA1, or Gd-IgA1. Think of it like a misfolded letter that the post office can't process.
These defective proteins trigger an immune response, forming clumps that get stuck in the kidney's tiny filters. Over time, the buildup causes inflammation, scarring, and progressive loss of kidney function. About one in four adults with IgAN eventually develop kidney failure and need dialysis or a transplant.
The cruel part? Many patients don't even know they have it until significant damage has already occurred. The disease often presents with nothing more than blood in the urine, and diagnosis requires a kidney biopsy.
How Trutakna Attacks the Problem at Its Source
Most existing IgAN drugs work downstream. They reduce blood pressure, limit protein leakage, or tamp down inflammation after the damage has started. Trutakna takes a fundamentally different approach: it goes after the root cause.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Trutakna is a fusion protein (a lab-engineered molecule) designed to act as a decoy. It mimics a natural receptor called TACI that sits on the surface of B cells. Two key survival signals, called BAFF and APRIL, normally bind to TACI and keep B cells alive and productive. Trutakna intercepts both of those signals before they ever reach the cell.
Imagine B cells as factories producing defective IgA1. BAFF and APRIL are the electricity keeping the factories running. Trutakna cuts the power.
By starving these B cells and plasma cells of their survival signals, Trutakna reduces the production of Gd-IgA1. Fewer defective proteins means fewer immune clumps, less kidney damage, and (hopefully) preserved kidney function over time.
This dual BAFF/APRIL blockade is what makes Trutakna unique. Other drugs in the IgAN space target endothelin receptors, complement pathways, or gut immune tissue. Trutakna is the first approved drug that hits both BAFF and APRIL simultaneously.
The Trial That Made It Happen
The FDA based its approval on the ORIGIN-3 Phase 3 trial, a global, double-blind study that randomized 431 patients to receive either Trutakna (150 mg injected under the skin once weekly) or placebo. The approval was based on a prespecified interim analysis of 203 patients at 36 weeks.
The primary goal was straightforward: measure whether Trutakna could reduce proteinuria (protein leaking into urine, a key marker of kidney damage) at 36 weeks.
The results were decisive. Patients on Trutakna saw a 46% reduction in proteinuria from baseline. The placebo group? Just 6.8%. The difference between the two groups was 42 percentage points, with a p-value under 0.0001. In clinical trial terms, that's about as clean a win as you'll ever see.
Beyond proteinuria, Trutakna also drove a 68% reduction in Gd-IgA1, that defective protein at the heart of the disease. This was a secondary endpoint measured without statistical adjustment, so it's observational rather than definitive. But it strongly suggests the drug is doing exactly what the science predicted.
Safety: The Placebo Lookalike
For a drug that suppresses part of the immune system, Trutakna's safety profile is remarkably tame. Adverse events occurred in 59.3% of treated patients versus 50% on placebo. Most were mild or moderate.
Infection rates tell an interesting story: 32% of Trutakna patients reported infections compared to 28% on placebo. That's a modest bump, not the dramatic increase you might expect from an immunosuppressant. Serious adverse events actually favored the drug: just 0.5% of Trutakna patients had a serious event, compared to 5% on placebo. No one in either group died.
The label does carry warnings about immunosuppression and infection risk, which is expected for any drug that dials down antibody production. But the clinical data so far paints a picture of a drug that's well-tolerated, especially given how aggressively it modifies the immune system.
Accelerated, Not Finished
One important caveat: this is an accelerated approval, not a full one. The FDA granted it based on proteinuria reduction, which is considered a "surrogate endpoint," a stand-in measurement that's reasonably likely to predict real clinical benefit but hasn't been conclusively proven to do so.
The big unanswered question is whether Trutakna actually slows long-term kidney function decline, measured by a metric called eGFR (estimated glomerular filtration rate, essentially how well your kidneys are filtering blood). That's the confirmatory endpoint still being tracked in the ongoing ORIGIN-3 trial.
Vera and the FDA have agreed to an accelerated eGFR analysis in Q3 2026. If those results are positive, Vera plans to submit a supplemental application by Q4 2026, with potential conversion to full approval in 2027. The clock is ticking, and the company seems confident.
Six Drugs, One Disease: The IgAN Gold Rush
The IgAN treatment landscape has transformed almost overnight. Just a few years ago, patients relied on generic blood pressure pills and the occasional round of steroids. Now the market has six approved therapies spanning four different mechanisms:
Fully approved: Tarpeyo (targeted-release budesonide, a localized steroid) and Filspari (sparsentan, a dual endothelin/angiotensin blocker) both have demonstrated long-term kidney protection.
Accelerated approvals: Vanrafia (atrasentan, an endothelin blocker approved April 2025), Fabhalta (iptacopan, a complement inhibitor approved August 2024), Voyxact (sibeprenlimab, an APRIL inhibitor approved November 2025), and now Trutakna.
The competitive dynamics are fascinating. Tarpeyo and Filspari have the strongest regulatory footing with full approvals and guideline endorsements from KDIGO (the global kidney disease guidelines body). The four accelerated-approval drugs still need to prove they protect kidney function long-term.
But Trutakna has a few things working in its favor. Its label is notably broad: no restrictions based on baseline proteinuria levels, no mention of neutralizing antibodies. Analysts have called it a "clean" label, which matters enormously for physician adoption.
The once-weekly self-injection via autoinjector is also a practical advantage. Patients can administer it at home rather than visiting a clinic.
Wall Street Is All In
The market's reaction to Vera's clinical data tells you everything. Analysts across the board have been pounding the table.
The consensus rating is a resounding Strong Buy, with 13 out of 14 analysts on one major platform recommending the stock. Price targets range from $33 to $110, with an average around $78, representing substantial upside from recent trading levels in the low $40s.
Cantor Fitzgerald has a $100 target. Goldman Sachs sits at $90. Analysts have modeled risk-adjusted atacicept revenues starting at $56 million in 2026 and ramping to $2.5 billion by 2033, with launch probability pegged at 95%.
Those are blockbuster numbers in a market that barely existed three years ago.
The Bigger Picture
Trutakna's approval is more than a win for Vera Therapeutics. It's a signal that IgAN has graduated from "orphan disease with no real treatments" to "one of the most competitive therapeutic markets in nephrology."
The real question now isn't whether patients will have options. It's how doctors will choose among them. Will they layer these drugs on top of each other? Will certain mechanisms prove superior for specific patient subgroups? The combination strategies are already being explored in clinical trials, and the answer will likely reshape nephrology practice for years.
For the roughly 200,000 Americans living with IgAN (and many more undiagnosed), the message is simpler. A disease that once offered a one-in-four chance of kidney failure now has six FDA-approved treatments, each attacking a different piece of the puzzle. That's not just progress; that's a revolution.
4 min read
The Obesity Pill That Could Crash Big Pharma's Party
Kailera Therapeutics' oral obesity pill just hit its goals in two late-stage China trials, delivering 11% weight loss and strong diabetes results. But the GI side effects are intense, and the real battle for the $22 billion oral obesity market is just getting started.
